论文部分内容阅读
目的探讨依替米星联合胸腺肽肠溶片方案治疗耐多药肺结核的疗效。方法 160例耐多药肺结核患者,采用随机数字法分为对照组和治疗组,每组80例。对照组采用常规抗痨方案治疗,治疗组在常规抗痨方案基础上采用依替米星联合胸腺肽肠溶片治疗,两组均完成12个月治疗,对比两组患者的病灶吸收总有效率、痰菌转阴率以及主要并发症发生率。结果治疗组患者病灶吸收总有效率为91.25%,显著优于对照组的72.50%(P<0.05)。治疗组患者在接受3、6、9、12个月治疗后,痰菌转阴率均明显高于对照组(P<0.05)。治疗组患者主要并发症发生率为5.00%,显著低于对照组的15.00%(P<0.05)。结论依替米星联合胸腺肽肠溶片方案治疗耐多药肺结核,病灶吸收总有效率高,痰菌转阴速度快,并发症发生率低,治疗肾功能正常的耐多药肺结核患者过程中,引起肾功能损害几率很低,停药后能很快恢复正常肾功能,治疗效果显著,值得推广应用。
Objective To investigate the efficacy of etimicin combined with thymosin enteric-coated tablets in the treatment of multidrug-resistant pulmonary tuberculosis. Methods 160 cases of multidrug-resistant pulmonary tuberculosis patients were divided into control group and treatment group by random number method, 80 cases in each group. The control group was treated with conventional anti-tuberculosis treatment. The treatment group was treated with etimicin plus thymosin enteric-coated tablets on the basis of routine anti-tuberculosis treatment. Both groups were treated for 12 months. The total effective rate of the two groups was compared. Sputum negative conversion rate and the incidence of major complications. Results The total effective rate of lesions absorption in treatment group was 91.25%, which was significantly better than that in control group (72.50%, P <0.05). After treatment for 3, 6, 9 and 12 months, the negative rate of sputum in the treatment group was significantly higher than that in the control group (P <0.05). The incidence of major complication in the treatment group was 5.00%, which was significantly lower than that in the control group (15.00%, P <0.05). Conclusion Etimicin combined with thymosin enteric-coated tablets for multi-drug resistant pulmonary tuberculosis, the total effective rate of absorption of the lungs, sputum negative fast, the incidence of complications is low, the treatment of patients with multi-drug resistant tuberculosis normal renal function, Caused a very low risk of renal damage, withdrawal can quickly restore normal renal function, the treatment effect is significant, it is worth promoting the application.